Immediate Nausea and Vomiting After the Administration of Non-ionic Contrast Media

2017-01-13 05:08:22 | BioPortfolio


The prevalence of nausea and vomiting after the administration of non-ionic contrast media has rarely been assessed. Thus, the aim of our study is to evaluate the prevalence and risk factors of nausea and vomiting after the exposure to the non-ionic contrast media for computed tomography examinations in adults.


There is no robust evidence or guideline for fasting prior to contrast-enhanced CT scan in patients. Substantial heterogeneity exists on fasting prior to contrast-enhanced CT worldwide. Through dedicated questionnaires, we plan to prospectively assess the prevalence and the risk factors for nausea and vomiting after the exposure to the non-ionic contrast media agent in adult patients undergoing computed tomography examinations.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Contrast Agent


Seoul National University Hospital
Korea, Republic of




Seoul National University Hospital

Results (where available)

View Results


Published on BioPortfolio: 2017-01-13T05:08:22-0500

Clinical Trials [669 Associated Clinical Trials listed on BioPortfolio]

Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma

Adult patients with chronic hepatitis B and cirrhosis of any etiology who are found to have suspected liver cancer are potentially eligible for the study. All enrolled patients will underg...

Prospective, Non-Randomized Evaluation of Carbon Dioxide Gas as a Contrast Agent in Comparison With Iodinated Contrast in Endovascular Aneurysm Repair

Endovascular repair of infrarenal abdominal aortic aneurysms (AAA) requires a contrast agent to identify the vascular anatomy and placement of the stent graft. Iodine contrast has traditi...

Control Post Endovascular Treatment of Aortic Aneurisms Through Magnetic Resonance and Ultrasound (SAFEVAR)

The aims of this study are to verify non-inferiority of magnetic resonance (MR) without contrast agent associated to color-Doppler ultrasound for the diagnosis of endoleaks after endovascu...

Optimization of Contrast Agent Dose in CT With Lean Body Weight

This study evaluates the different enhancement using a contrast agent dose in computed tomography based on total body weight or based on lean body weight. Half of participants will receive...

Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancr...

PubMed Articles [6197 Associated PubMed Articles listed on BioPortfolio]

FeO-ZIF-8 assemblies as pH and glutathione responsive T-T switching magnetic resonance imaging contrast agent for sensitive tumor imaging in vivo.

A small Fe3O4 nanoparticles-based T1 contrast agent was assembled into a pH- and glutathione-responsive T2-T1 switching contrast agent, Fe3O4-ZIF-8. In vivo T1-weighted images of mice showed that Fe3O...

Ion chamber response to kilovoltage x-rays in the presence of a contrast agent.

Contrast enhanced radiotherapy is a relatively new treatment modality in which a radiological contrast agent is uploaded into a tumor that is subsequently irradiated with kilovoltage x-ray beams thus ...

Janus nanoparticles for contrast enhancement of T-T dual mode magnetic resonance imaging.

The accuracy of magnetic resonance imaging (MRI) scanning can be improved using a multifunctional nanosystem having T1-T2 dual contrast enhancement. Specifically, the combination of both T1 and T2 eff...

Technical note: Evaluation of kV CBCT enhancement using a liver specific contrast agent for stereotactic body radiation therapy image guidance.

To evaluate possible use for cone-beam CT guidance, this phantom study evaluated the contrast enhancement provided by Gadoxetate Disodium (Primovist CAN/EU, or Eovist USA, Bayer Healthcare), a contras...

Update on Gadolinium-Based Contrast Agent-Enhanced Imaging in the Genitourinary System.

The purpose of this article is to review gadolinium-based contrast agent (GBCA)-enhanced MRI applications in the genitourinary system.

Medical and Biotech [MESH] Definitions

A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.

An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Thorium oxide (ThO2). A radiographic contrast agent that was used in the early 1930s through about 1954. High rates of mortality have been linked to its use and it has been shown to cause liver cancer.

A method of delineating blood vessels by subtracting a tissue background image from an image of tissue plus intravascular contrast material that attenuates the X-ray photons. The background image is determined from a digitized image taken a few moments before injection of the contrast material. The resulting angiogram is a high-contrast image of the vessel. This subtraction technique allows extraction of a high-intensity signal from the superimposed background information. The image is thus the result of the differential absorption of X-rays by different tissues.

A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

More From BioPortfolio on "Immediate Nausea and Vomiting After the Administration of Non-ionic Contrast Media"

Quick Search


Searches Linking to this Trial